Last reviewed · How we verify
Lidocaine (Zingo)
Lidocaine (Zingo) is a Local anesthetic Small molecule drug developed by Lee's Pharmaceutical Limited. It is currently in Phase 3 development for Topical anesthesia prior to needle procedures (venipuncture, intravenous access) in pediatric and adult patients. Also known as: Zingo.
Lidocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Lidocaine, also known as Zingo, is a small molecule that acts as a sodium channel alpha subunit blocker. It is used to treat various conditions, including pain, postoperative pain, and shoulder pain, often in conjunction with other interventions such as blocks and patient-controlled analgesia.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lidocaine (Zingo) |
|---|---|
| Also known as | Zingo |
| Sponsor | Lee's Pharmaceutical Limited |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Lidocaine reversibly binds to voltage-gated sodium channels on the inner surface of nerve cell membranes, inhibiting sodium influx and preventing depolarization. This blocks the generation and propagation of action potentials in sensory nerves, resulting in local anesthesia. Zingo is a needle-free, powder-based formulation designed for rapid topical anesthesia prior to needle procedures.
Approved indications
- Topical anesthesia prior to needle procedures (venipuncture, intravenous access) in pediatric and adult patients
Common side effects
- Erythema at application site
- Blanching at application site
- Edema at application site
- Transient local reactions
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Closed Versus Open Lateral Internal Sphincterotomy for Chronic Anal Fissure (NA)
- OMT for Adhesive Capsulitis (PHASE4)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine (Zingo) CI brief — competitive landscape report
- Lidocaine (Zingo) updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI
Frequently asked questions about Lidocaine (Zingo)
What is Lidocaine (Zingo)?
How does Lidocaine (Zingo) work?
What is Lidocaine (Zingo) used for?
Who makes Lidocaine (Zingo)?
Is Lidocaine (Zingo) also known as anything else?
What drug class is Lidocaine (Zingo) in?
What development phase is Lidocaine (Zingo) in?
What are the side effects of Lidocaine (Zingo)?
What does Lidocaine (Zingo) target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Lee's Pharmaceutical Limited — full pipeline
- Therapeutic area: All drugs in Anesthesia / Pain Management
- Indication: Drugs for Topical anesthesia prior to needle procedures (venipuncture, intravenous access) in pediatric and adult patients
- Also known as: Zingo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing